Yila

Figure template · Workflow · 4:3

Drug Development Pipeline Figure: Target Discovery to Post-Market

A landscape swimlane figure that follows a drug candidate from target discovery and lead optimization through preclinical studies, IND filing, three clinical phases, NDA/BLA review and post-market surveillance, with a compound funnel and stage timelines along the bottom.

Updated Oct 16, 2026Reviewed by Roxy Liu9.8K1.62K

Prompt

Create a scientific figure about: Drug development pipeline from target discovery, hit identification and lead optimization through preclinical studies, IND filing, Phase I–III clinical trials, NDA/BLA review and post-market surveillance, with stage durations, trial sizes, the compound funnel and stage success rates. Visual style: Clean Vector. Requirements: publication-ready scientific quality, clear labels and directional arrows where appropriate, avoid cartoon or stock-photo look, composition optimized for research papers and academic slides.

What this template is

Six colour-coded stages run left to right. Discovery moves from target validation and hit identification through hit-to-lead SAR work to lead optimization against ADMET criteria; preclinical development adds in vitro toxicology, in vivo pharmacology, animal pharmacokinetics and GLP studies. A vertical IND bar opens the clinical block, where Phase I tests safety in healthy volunteers, Phase II explores dose and efficacy in patients, and Phase III confirms efficacy in large multicentre trials. Regulatory review and Phase IV surveillance close the line. A reader should come away seeing attrition: thousands of compounds enter, one drug leaves, and each later failure costs more.

Elements to label

  • Target discovery

    Top-left box listing genomics, proteomics and bioinformatics; swap in the omics or genetic evidence your target actually rests on.

  • Hit identification

    Expand HTS as high-throughput screening, and name virtual screening separately if you ran it alongside the wet-lab screen.

  • Hit-to-lead and lead optimization

    Keep SAR and ADMET as abbreviations with their full forms in brackets, and state the potency and selectivity goals.

  • Preclinical development

    The green column lists toxicology, pharmacology models, rodent and primate PK and GLP work; italicize only in vitro and in vivo.

  • IND filing

    A vertical black-outlined bar between the preclinical and clinical blocks; keep the rotated label short enough to read in one line.

  • Phase I–III clinical trials

    Three columns shading from pale yellow to orange, each giving purpose, duration and participant numbers in the same row order.

  • NDA/BLA review and approval

    Purple column split into submission above and authorization below; replace the FDA wording if your audience works under another regulator.

  • Compound funnel and success rates

    A band of arrows under the columns carries compound counts and transition rates; caption them as commonly cited approximations.

Where it is used

  • Course handout
  • Grant proposal
  • Defense slides
  • Academic poster

What reviewers look for

  • HTS is expanded wrongly

    The sample spells HTS out as high-throughput virtual screening. HTS means physical screening of compound libraries; virtual screening is a separate computational method, and a pharmacology reader will notice the mix-up at once.

  • Stage numbers do not line up

    The clinical sub-columns are numbered 1, 2 and 4, while the IND column carries a lone 3 in the header row, clashing with the six top-level stage numbers. Renumber consistently or drop the sub-column numbers.

  • Phase IV text is duplicated and garbled

    The post-market column repeats its long-term safety note twice, and the second copy ends in misspelled nonsense words. Ask for a single clean note and proofread every word in that column before downloading.

  • Rates and durations carry no source

    The success rates, approval rate, compound counts and total timeline are typical industry approximations, not figures from a cited analysis. In a paper or grant, replace them with numbers from your own reference and cite it.

How to use it in Yila

  1. 1Pick a figure
  2. 2Describe your subject and the steps to stress
  3. 3Refine it in chat, then download the PNG

Tips

Do

  • State the modality, small molecule or biologic, so the review column keeps only NDA or only BLA.
  • If your readers work under a regulator other than the FDA, name it so the IND and review labels match their system.
  • To focus on one stage, ask for that column to be enlarged and the other stages compressed into a slim timeline.

Avoid

  • Do not keep the second approved-drug label beside the total-time arrow; the endpoint needs stating only once.
  • Do not present the bottom-row percentages as data from your own programme unless you can cite where they came from.

Questions

Can I put this pipeline figure straight into my paper?

Treat it as a starting draft. It is an AI-generated image, and the sample has a wrong HTS expansion, misaligned stage numbers and garbled Phase IV text, while its success rates have no source. Check each column and keep refining it in chat until it matches the literature you cite.

Can I change one column's wording or colours?

It is not editable element by element and it is not a vector graphic. You can refine it by chatting in Yila, for example asking it to correct the HTS label or recolour the clinical columns, and it will regenerate the whole figure from your instructions.

What format is delivered?

An AI-generated PNG image in a 4:3 landscape frame, which suits a slide or a full-width background figure. The columns hold a lot of small text, so check that it stays legible before enlarging it for a poster.

Is the template free to use?

Viewing this page and the sample costs nothing. Generating and refining the figure in Yila consumes credits, and a new account receives 2,500 credits, so you can produce a first version and then decide which columns need changing for your topic.

Can it show only the clinical phases in more detail?

Yes. Ask for discovery and preclinical work to shrink into a narrow column on the left, enlarge Phase I–III, and add the primary endpoint and design for each phase, such as dose escalation or a randomized controlled trial. That version suits clinical pharmacology teaching or a protocol overview.

Can it follow a non-US regulatory pathway?

Yes. Describe the pathway you need, such as a European marketing authorization, and it will relabel the IND bar and the review column accordingly. If you want stage durations or approval rates shown, give it the figures from your own source rather than keeping the sample's.

Download sample PNG